Abstract Number: 95 • 2014 ACR/ARHP Annual Meeting
Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First- or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept
Background/Purpose: There are currently very limited comparative published data on the characteristics, healthcare costs, and biologic persistence among patients with RA who have been treated…
ACR Meeting Abstracts